Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Replication of 13 genome-wide association (GWA)-validated risk variants for type 2 diabetes in Pakistani populations

Tools
- Tools
+ Tools

Rees, Simon D., Hydrie, M. Z. I., Shera, A. S., Kumar, Sudhesh, O'Hare, J. Paul, Barnett, A. H., Basit, A. and Kelly, M. Ann (2011) Replication of 13 genome-wide association (GWA)-validated risk variants for type 2 diabetes in Pakistani populations. Diabetologia, Volume 54 (Number 6). pp. 1368-1374. doi:10.1007/s00125-011-2063-2

Research output not available from this repository, contact author.
Official URL: http://dx.doi.org/10.1007/s00125-011-2063-2

Request Changes to record.

Abstract

Recent genome-wide association (GWA) studies and subsequent replication studies have greatly increased the number of validated type 2 diabetes susceptibility variants, but most of these have been conducted in European populations. Despite the high prevalence of the disease in South Asians, studies investigating GWA-validated type 2 diabetes risk variants in this ethnic group are limited. We investigated 30 single nucleotide polymorphisms (SNPs), predominantly derived from recent GWA studies, to determine if and to what extent these variants affect type 2 diabetes risk in two Punjabi populations, originating predominantly from the District of Mirpur, Pakistan.

Thirty SNPs were genotyped in 1,678 participants with type 2 diabetes and 1,584 normoglycaemic control participants from two populations; one resident in the UK and one indigenous to the District of Mirpur.

SNPs in or near PPARG, TCF7L2, FTO, CDKN2A/2B, HHEX/IDE, IGF2BP2, SLC30A8, KCNQ1, JAZF1, IRS1, KLF14, CHCHD9 and DUSP9 displayed significant (p < 0.05) associations with type 2 diabetes, with similar effect sizes to those seen in European populations. A constructed genetic risk score was associated with type 2 diabetes (p = 5.46 x 10(-12)), BMI (p = 2.25 x 10(-4)) and age at onset of diabetes (p = 0.002).

We have demonstrated that 13 variants confer an increased risk of type 2 diabetes in our Pakistani populations; to our knowledge this is the first time that SNPs in or near KCNQ1, JAZF1, IRS1, KLF14, CHCHD9 and DUSP9 have been significantly associated with the disease in South Asians. Large-scale studies and meta-analyses of South Asian populations are needed to further confirm the effect of these variants in this ethnic group.

Item Type: Journal Article
Subjects: R Medicine > RC Internal medicine
Divisions: Faculty of Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH): Pakistanis -- Health and hygiene -- Great Britain, Non-insulin-dependent diabetes -- Genetic aspects, Non-insulin-dependent diabetes -- Susceptibility, Genomics
Journal or Publication Title: Diabetologia
Publisher: Springer
ISSN: 0012-186X
Official Date: June 2011
Dates:
DateEvent
June 2011Published
Volume: Volume 54
Number: Number 6
Page Range: pp. 1368-1374
DOI: 10.1007/s00125-011-2063-2
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Restricted or Subscription Access
Funder: Diabetes UK, Pfizer Ltd., Sanofi aventis (Firm), Servier Laboratories Ltd., Merck Sharp & Dohme, Schering-Plough Corporation, Takeda UK (Firm), Produits Roche S.A., Daiichi-Sankyo UK, Boehringer Ingelheim Pharmaceuticals, Eli Lilly and Company, Novo Nordisk, Bristol-Myers Squibb Company, Solvay Health Care, Assurance Medical Society UK
Grant number: 07/0003512 (DUK), 09/0003926 (DUK)

Data sourced from Thomson Reuters' Web of Knowledge

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item
twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us